Back to Directory
Antev
Greater London
Founded 2013
Long-acting GnRH antagonist for prostate cancer and urinary retention
Antev is a clinical-stage biopharmaceutical company developing a long-acting gonadotropin-releasing hormone (GnRH) antagonist that suppresses testosterone production.
Its lead peptide therapy is being developed for men with advanced prostate cancer, including those at high cardiovascular risk, and for men experiencing a first episode of acute urinary retention caused by an enlarged prostate.
The candidate has completed early-stage clinical trials and is progressing towards later-phase studies.